Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Lung Cancer

Volumn 93, Issue , 2016, Pages 59-68

  Tan, Chee Seng ^a   Cho, Byoung Chul ^b   Soo, Ross A ^a,c,d  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Yonsei University College of Medicine   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Epidermal growth factor receptor mutations; HM61713; Non small cell lung cancer; Osimertinib; Rociletinib; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; ASP 8273; AVITINIB; AZD 3759; BRIGATINIB; DACOMITINIB; EGF 816; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HM 61713; OSIMERTINIB; ROCILETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENE MUTATION; HUMAN; MENINGITIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PATHOLOGY; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84959338411     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.003     Document Type: Review

References (59)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
3. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
4. Shi Y., Au J.S.K., Thongprasert S., Srinivasan S., Tsai C.M., Khoa M.T., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 2014, 9:154-162.
5. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
7. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
8. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
9. Sequist L.V., Yang J.C.H., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013, 31:3327-3334.
10. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
11. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
12. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
13. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2070-2075.
14. Ou S.H.I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap?. Crit. Rev. Oncol. Hematol. 2012, 83:407-421.
15. Janjigian Y.Y., Smit E.F., Groen H.J.M., Horn L., Gettinger S., Camidge D.R., et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014, 4:1036-1045.
16. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
17. Cross D.A.E., Ashton S.E., Ghiorghiu S., Eberlein C., Nebhan C.A., Spitzler P.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014, 4:1046-1061.
18. Jänne P.A., Yang J.C.H., Kim D.W., Planchard D., Ohe Y., Ramalingam S.S., et al. AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 372:1689-1699.
19. Ramalingam S.S., et al. AZD9291 in Treatment-Naïve EGFRm Advanced NSCLC: AURA First-Line Cohort. 16th World Conf. Lung Cancer 2015.
20. Mitsudomi T., et al. AZD9291 in pre-treated T790 M Positive Advanced NSCLC: AURA2 Phase II Study. 16th World Conf. Lung Cancer 2015.
21. Ahn M.J., et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from Phase II studies. Eur. J. Cancer 2015, 51. Abstract #3083.
22. Walter A.O., Sjin R.T.T., Haringsma H.J., Sun J., Ohashi K., Lee K., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov. 2013, 3:1404-1415.
23. Sequist L.V., Soria J.C., Goldman J.W., Wakelee H.A., Gadgeel S.M., Varga A., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:1700-1709.
24. Goldman J.W., et al. Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. 16th World Conf. Lung Cancer 2015.
25. Lee K.O., et al. Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor. Cancer Res. 2014, 74. Abstract # LB-100.
26. Park K., et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). 2015 ASCO Annual Meeting 2015.
27. Tan D.S., et al. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. 2015 ASCO Annual Meeting 2015.
28. S.Kasibhatla J., Li C., Tompkins M.T., Vaillancourt J., Anderson A.C.Pferdekamper, et al. EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC. Cancer Res. 2014, 74. Abstract #1733.
29. Sakagami H., Konagai S., Yamamoto H., Tanaka H., Matsuya T., Mori M., et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790 M resistance mutations. Cancer Res. 2014, 74. Abstract #1728.
30. Goto Y., et al. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. 2015 ASCO Annual Meeting 2015.
31. Yu H.A., et al. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. 2015 ASCO Annual Meeting 2015.
32. Rivera V.M., et al. AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790 M in cell and mouse models of NSCLC. Cancer Res. 2014, 72. Abstract #1794.
33. Thress K.S., Paweletz C.P., Felip E., Cho B.C., Stetson D., Dougherty B., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015, 21:560-562.
34. Ercan D., Choi H.G., Yun C.H., Capelletti M., Xie T., Eck M.J., et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res. 2015, 21:3913-3923.
35. Niederst M.J., Hu H., Mulvey H.E., Lockerman E.L., Garcia A.R., Piotrowska Z., et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 2015, 21:3924-3933.
36. Eberlein C.A., Stetson D., Markovets A.A., Al-Kadhimi K.J., Lai Z., Fisher P.R., et al. Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015, 12:2489-2500.
37. Oxnard G.R., et al. Mechanisms of acquired resistance to AZD9291 in EGFR T790 M positive lung cancer. 16th World Conf. Lung Cancer 2015.
38. Planchard D., Loriot Y., André F., Gobert A., Auger N., Lacroix L., et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 2015, 26:2073-2078.
39. Piotrowska Z., Niederst M.J., Karlovich C.A., Wakelee H.A., Neal J.W., Mino-Kenudson M., et al. Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-positive cancers with a third generation EGFR inhibitor. Cancer Discov. 2015, 5:713-722.
40. Kim D.W., et al. AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. 2015 ASCO Annual Meeting 2015.
41. Sundar R., Soong R., Cho B.C., Brahmer J.R., Soo R.A. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85:101-109.
42. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:1627-1639.
43. Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:123-135.
44. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015, 161:205-214.
45. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013, 3:1355-1363.
46. Oxnard G.R., et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. 2015 ASCO Annual Meeting 2015.
47. AstraZeneca pauses two lung cancer drug combination trials. (accessed 10.11.15). http://www.reuters.com/article/2015/10/09/astrazeneca-cancer-idUSL8N12920M20151009#Ssxell1uhLX3iwPp.97.
48. Johnson D.B., Wallender E.K., Cohen D.N., Likhari S.S., Zwerner J.P., Powers J.G., et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol. Res. 2013, 1:373-377.
49. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 2013, 368:1365-1366.
50. Luke J.J., Ott P.A. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?. Expert Opin. Pharmacother. 2013, 14:2457-2462.
51. Tan C.S., Gilligan D., Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015, 16:e447-e459.
52. de Bruin E.C., McGranahan N., Mitter R., Salm M., Wedge D.C., Yates L., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014, 346(80):251-256.
53. Zhang J., Fujimoto J., Zhang J., Wedge D.C., Song X., Zhang J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346:256-259.
54. Schwarzenbach H., Hoon D.S.B., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
55. Qiu M., Wang J., Xu Y., Ding X., Li M., Jiang F., et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2015, 24:206-212.
56. Sequist L.V., et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). 2015 ASCO Annual Meeting 2015.
57. Mok T., Wu Y.L., Lee J.S., Yu C.J., Sriuranpong V., Sandoval-Tan J., et al. Detection and dynamic changes of egfr mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 2015, 21:3196-3203.
58. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20:1698-1705.
59. Thress K.S., Brant R., Carr T.H., Dearden S., Jenkins S., Brown H., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015, 15:30073-30078.